| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 29 | 2024 | 5061 | 2.850 |
Why?
|
| Carcinoma, Pancreatic Ductal | 14 | 2024 | 1724 | 1.610 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 600 | 1.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2023 | 15862 | 1.390 |
Why?
|
| Biliary Tract Neoplasms | 4 | 2023 | 167 | 1.220 |
Why?
|
| Neoplasms | 29 | 2023 | 15193 | 1.160 |
Why?
|
| Paclitaxel | 10 | 2023 | 1996 | 1.140 |
Why?
|
| Immunotherapy | 8 | 2023 | 3341 | 1.130 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 235 | 1.090 |
Why?
|
| Deoxycytidine | 11 | 2023 | 1353 | 1.050 |
Why?
|
| Trifluridine | 2 | 2022 | 30 | 1.020 |
Why?
|
| Adenocarcinoma | 10 | 2023 | 7789 | 0.980 |
Why?
|
| Colorectal Neoplasms | 6 | 2024 | 3578 | 0.900 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2024 | 1331 | 0.850 |
Why?
|
| Esophageal Neoplasms | 5 | 2023 | 3168 | 0.830 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14289 | 0.810 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 4757 | 0.800 |
Why?
|
| Bile Duct Neoplasms | 5 | 2023 | 493 | 0.750 |
Why?
|
| Anilides | 1 | 2022 | 268 | 0.730 |
Why?
|
| Bevacizumab | 4 | 2023 | 938 | 0.700 |
Why?
|
| Pyridines | 4 | 2022 | 1244 | 0.680 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2023 | 962 | 0.670 |
Why?
|
| Vaccines | 1 | 2024 | 389 | 0.650 |
Why?
|
| Humans | 106 | 2024 | 261506 | 0.650 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2022 | 3251 | 0.630 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2022 | 1048 | 0.600 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.600 |
Why?
|
| Cholangiocarcinoma | 4 | 2023 | 493 | 0.590 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.590 |
Why?
|
| Albumins | 5 | 2023 | 258 | 0.580 |
Why?
|
| Dibenzazepines | 1 | 2016 | 4 | 0.560 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2023 | 2341 | 0.560 |
Why?
|
| Interleukin-10 | 4 | 2020 | 478 | 0.550 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2016 | 99 | 0.530 |
Why?
|
| Ifosfamide | 2 | 2014 | 344 | 0.530 |
Why?
|
| Stomach Neoplasms | 4 | 2023 | 2278 | 0.530 |
Why?
|
| Alanine | 1 | 2016 | 240 | 0.520 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 615 | 0.520 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 479 | 0.520 |
Why?
|
| Enzyme Inhibitors | 3 | 2023 | 1879 | 0.520 |
Why?
|
| Esophagogastric Junction | 2 | 2023 | 543 | 0.510 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 210 | 0.500 |
Why?
|
| Gallbladder Neoplasms | 3 | 2023 | 245 | 0.490 |
Why?
|
| Maximum Tolerated Dose | 9 | 2023 | 1290 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.480 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.480 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2013 | 21 | 0.460 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.460 |
Why?
|
| Benzopyrans | 1 | 2013 | 41 | 0.450 |
Why?
|
| Male | 58 | 2024 | 123000 | 0.450 |
Why?
|
| Leucovorin | 5 | 2020 | 332 | 0.440 |
Why?
|
| Middle Aged | 50 | 2024 | 86204 | 0.440 |
Why?
|
| Fluorouracil | 7 | 2021 | 1944 | 0.440 |
Why?
|
| Receptors, Notch | 1 | 2016 | 383 | 0.430 |
Why?
|
| Aged | 41 | 2023 | 70117 | 0.420 |
Why?
|
| Female | 59 | 2024 | 141928 | 0.420 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 213 | 0.420 |
Why?
|
| Prognosis | 16 | 2023 | 21713 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 4938 | 0.380 |
Why?
|
| Aged, 80 and over | 24 | 2022 | 29902 | 0.380 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2021 | 1249 | 0.380 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.360 |
Why?
|
| Germ Cells | 3 | 2022 | 335 | 0.360 |
Why?
|
| Anus Neoplasms | 1 | 2014 | 411 | 0.350 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 1248 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 588 | 0.340 |
Why?
|
| Pyrazoles | 4 | 2023 | 1471 | 0.340 |
Why?
|
| Brain Diseases | 1 | 2012 | 403 | 0.340 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 10331 | 0.330 |
Why?
|
| Adult | 34 | 2022 | 77950 | 0.330 |
Why?
|
| Quinolones | 3 | 2021 | 160 | 0.320 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2008 | 70 | 0.320 |
Why?
|
| Treatment Outcome | 20 | 2022 | 32848 | 0.310 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 37 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.310 |
Why?
|
| Pancreatectomy | 3 | 2021 | 652 | 0.310 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 3472 | 0.300 |
Why?
|
| Hypertension | 1 | 2016 | 1503 | 0.300 |
Why?
|
| Azepines | 2 | 2017 | 124 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6207 | 0.290 |
Why?
|
| Aurora Kinase A | 2 | 2017 | 202 | 0.280 |
Why?
|
| Drugs, Investigational | 2 | 2017 | 135 | 0.280 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 222 | 0.270 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 13658 | 0.270 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 2518 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10035 | 0.260 |
Why?
|
| Aromatase Inhibitors | 1 | 2008 | 305 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2024 | 2054 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2020 | 9180 | 0.260 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 739 | 0.250 |
Why?
|
| Disease-Free Survival | 6 | 2022 | 10001 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5319 | 0.250 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 1546 | 0.250 |
Why?
|
| Precision Medicine | 3 | 2022 | 1154 | 0.250 |
Why?
|
| Piperazines | 3 | 2023 | 2101 | 0.250 |
Why?
|
| Phthalazines | 3 | 2023 | 253 | 0.250 |
Why?
|
| Capecitabine | 3 | 2022 | 388 | 0.240 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11538 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 4367 | 0.240 |
Why?
|
| Benzoxazoles | 1 | 2024 | 41 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2023 | 37905 | 0.230 |
Why?
|
| Exanthema | 2 | 2024 | 211 | 0.230 |
Why?
|
| Mucositis | 1 | 2023 | 148 | 0.220 |
Why?
|
| Drug Combinations | 2 | 2022 | 621 | 0.220 |
Why?
|
| Hydrazines | 2 | 2022 | 208 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2864 | 0.220 |
Why?
|
| Leiomyosarcoma | 1 | 2024 | 223 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2021 | 5437 | 0.210 |
Why?
|
| Microsatellite Instability | 2 | 2021 | 400 | 0.210 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 33 | 0.210 |
Why?
|
| Pyrimidines | 3 | 2020 | 3518 | 0.200 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 200 | 0.200 |
Why?
|
| Stress, Psychological | 1 | 2009 | 1000 | 0.200 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2022 | 141 | 0.200 |
Why?
|
| Celiac Plexus | 1 | 2021 | 13 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2023 | 199 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 2594 | 0.200 |
Why?
|
| Disease Progression | 3 | 2023 | 6682 | 0.200 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 168 | 0.200 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 37 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 1216 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 992 | 0.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 4638 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 521 | 0.190 |
Why?
|
| Adenine | 1 | 2024 | 631 | 0.190 |
Why?
|
| Nitroimidazoles | 1 | 2021 | 100 | 0.190 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 846 | 0.190 |
Why?
|
| Stomach | 1 | 2023 | 387 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 6550 | 0.190 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 297 | 0.180 |
Why?
|
| Karyopherins | 1 | 2021 | 136 | 0.180 |
Why?
|
| Metformin | 1 | 2024 | 378 | 0.180 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 119 | 0.180 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.180 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 15694 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2022 | 731 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 246 | 0.170 |
Why?
|
| United States | 5 | 2020 | 15433 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 665 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2021 | 211 | 0.170 |
Why?
|
| Organoplatinum Compounds | 2 | 2020 | 702 | 0.160 |
Why?
|
| Diamines | 1 | 2018 | 24 | 0.160 |
Why?
|
| Administration, Oral | 3 | 2018 | 1544 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 14889 | 0.160 |
Why?
|
| Peptides | 1 | 2024 | 1479 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 480 | 0.150 |
Why?
|
| Biomarkers | 5 | 2023 | 5047 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 986 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 587 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2021 | 428 | 0.150 |
Why?
|
| Itraconazole | 1 | 2017 | 77 | 0.150 |
Why?
|
| Esomeprazole | 1 | 2017 | 31 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 172 | 0.150 |
Why?
|
| Cadherins | 1 | 2020 | 660 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 1506 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 223 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2020 | 351 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 6915 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 591 | 0.140 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2021 | 710 | 0.140 |
Why?
|
| Rifampin | 1 | 2017 | 191 | 0.140 |
Why?
|
| Uracil | 1 | 2016 | 64 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 739 | 0.140 |
Why?
|
| Cancer Pain | 1 | 2021 | 312 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 334 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 2138 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Psychometrics | 1 | 2020 | 937 | 0.140 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 409 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1350 | 0.130 |
Why?
|
| Epidemiologic Methods | 2 | 2021 | 254 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2017 | 700 | 0.130 |
Why?
|
| Survival Rate | 5 | 2021 | 12221 | 0.130 |
Why?
|
| Gemfibrozil | 1 | 2014 | 6 | 0.130 |
Why?
|
| Diarrhea | 3 | 2024 | 686 | 0.130 |
Why?
|
| Ketoconazole | 1 | 2014 | 34 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.130 |
Why?
|
| Cetuximab | 2 | 2014 | 472 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 852 | 0.130 |
Why?
|
| CA-19-9 Antigen | 3 | 2022 | 144 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1392 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2021 | 1529 | 0.130 |
Why?
|
| Electrocardiography | 2 | 2017 | 1145 | 0.120 |
Why?
|
| Cisplatin | 3 | 2021 | 2432 | 0.120 |
Why?
|
| Isoflavones | 1 | 2014 | 72 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.120 |
Why?
|
| Bayes Theorem | 3 | 2023 | 1021 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.120 |
Why?
|
| Oximes | 1 | 2014 | 175 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 1688 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 2 | 2021 | 3976 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2022 | 1823 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2020 | 2326 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 1299 | 0.110 |
Why?
|
| Neoplasm Metastasis | 6 | 2022 | 5112 | 0.110 |
Why?
|
| Mitomycin | 1 | 2014 | 208 | 0.110 |
Why?
|
| Genomics | 2 | 2021 | 2738 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1046 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2086 | 0.110 |
Why?
|
| Mutation | 6 | 2023 | 15179 | 0.110 |
Why?
|
| Carboplatin | 1 | 2016 | 823 | 0.110 |
Why?
|
| Oncolytic Virotherapy | 1 | 2016 | 280 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 792 | 0.110 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Gingival Neoplasms | 1 | 2012 | 6 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2020 | 12873 | 0.110 |
Why?
|
| DNA Repair | 1 | 2020 | 1872 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 3981 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.110 |
Why?
|
| Trastuzumab | 2 | 2020 | 696 | 0.110 |
Why?
|
| Plasmacytoma | 1 | 2013 | 111 | 0.100 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 3022 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 4975 | 0.100 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2012 | 128 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.100 |
Why?
|
| Adolescent | 4 | 2023 | 31252 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2016 | 1694 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 607 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4320 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 7551 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.090 |
Why?
|
| Bone Marrow Purging | 1 | 2009 | 86 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2027 | 0.090 |
Why?
|
| Heart | 1 | 2016 | 1223 | 0.090 |
Why?
|
| Imidazoles | 1 | 2014 | 999 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1265 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2022 | 604 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2017 | 11965 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 489 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.080 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2007 | 155 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 181 | 0.070 |
Why?
|
| Cytokines | 1 | 2016 | 2809 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.070 |
Why?
|
| Nausea | 2 | 2023 | 525 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3890 | 0.070 |
Why?
|
| Safety | 2 | 2021 | 465 | 0.070 |
Why?
|
| Melanoma | 2 | 2021 | 5317 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 1391 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 538 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2008 | 262 | 0.070 |
Why?
|
| Busulfan | 1 | 2009 | 764 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2012 | 945 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4557 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5539 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 643 | 0.060 |
Why?
|
| Life Style | 1 | 2008 | 612 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2016 | 6869 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5767 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 26 | 0.060 |
Why?
|
| Health Promotion | 1 | 2008 | 502 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 1144 | 0.060 |
Why?
|
| Quinazolines | 1 | 2008 | 923 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2008 | 787 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 265 | 0.050 |
Why?
|
| Incidence | 2 | 2012 | 5673 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 1914 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4892 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 3001 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 263 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1664 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 571 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 158 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 253 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 2843 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 371 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.050 |
Why?
|
| Remission Induction | 1 | 2007 | 3569 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 413 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 272 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 1382 | 0.050 |
Why?
|
| Taxoids | 2 | 2016 | 967 | 0.050 |
Why?
|
| Indium Radioisotopes | 1 | 2020 | 65 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 391 | 0.050 |
Why?
|
| Topotecan | 1 | 2021 | 239 | 0.050 |
Why?
|
| Benzazepines | 1 | 2021 | 108 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 354 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 323 | 0.050 |
Why?
|
| Income | 1 | 2021 | 222 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 287 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 160 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2020 | 222 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 288 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 267 | 0.050 |
Why?
|
| Clonal Evolution | 1 | 2022 | 253 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2020 | 266 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 2020 | 178 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 344 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 212 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 669 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 612 | 0.040 |
Why?
|
| Granzymes | 1 | 2018 | 91 | 0.040 |
Why?
|
| Pyrazines | 1 | 2021 | 495 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 100 | 0.040 |
Why?
|
| Everolimus | 1 | 2020 | 415 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 676 | 0.040 |
Why?
|
| Fatigue | 2 | 2016 | 1239 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2232 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5687 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 498 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 1008 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 925 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 718 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 59536 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 1678 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 452 | 0.040 |
Why?
|
| Capsules | 1 | 2016 | 53 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 49 | 0.040 |
Why?
|
| Tablets | 1 | 2016 | 53 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2016 | 70 | 0.040 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 2016 | 10 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2016 | 66 | 0.030 |
Why?
|
| Testis | 1 | 2020 | 717 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 334 | 0.030 |
Why?
|
| Thymine | 1 | 2016 | 46 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 284 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 1904 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2016 | 113 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 17523 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 799 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C8 Inhibitors | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pain Management | 1 | 2021 | 668 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 435 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 155 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 29 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 460 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2008 | 8223 | 0.030 |
Why?
|
| Pregnancy | 1 | 2008 | 7573 | 0.030 |
Why?
|
| Uveal Neoplasms | 1 | 2016 | 176 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2023 | 2295 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 344 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8873 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 256 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 706 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 737 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 34495 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 4298 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2016 | 204 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 497 | 0.030 |
Why?
|
| Warfarin | 1 | 2014 | 152 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2022 | 1423 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2014 | 553 | 0.030 |
Why?
|
| Jaundice, Obstructive | 1 | 2013 | 16 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 4988 | 0.030 |
Why?
|
| Suramin | 1 | 2012 | 14 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1823 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1450 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 7548 | 0.030 |
Why?
|
| Genome, Human | 1 | 2020 | 1869 | 0.030 |
Why?
|
| Leukopenia | 1 | 2012 | 151 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 223 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 1533 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 2146 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2015 | 825 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1341 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 2927 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 689 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1130 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 2961 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5637 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2265 | 0.020 |
Why?
|
| Palliative Care | 1 | 2021 | 2037 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 690 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2291 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3151 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 787 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3230 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 6942 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1818 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3570 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8865 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.020 |
Why?
|